Edition:
United States

Vericel Corp (VCEL.OQ)

VCEL.OQ on NASDAQ Stock Exchange Capital Market

4.72USD
8 Dec 2017
Change (% chg)

$-0.17 (-3.57%)
Prev Close
$4.90
Open
$4.90
Day's High
$5.00
Day's Low
$4.68
Volume
60,854
Avg. Vol
99,390
52-wk High
$6.30
52-wk Low
$2.25

Chart for

About

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through... (more)

Overall

Beta: 2.99
Market Cap(Mil.): $155.10
Shares Outstanding(Mil.): 32.82
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap Financial

* VERICEL ENTERS INTO EXPANDED $25 MILLION DEBT FACILITIES WITH SILICON VALLEY BANK AND MIDCAP FINANCIAL TO SUPPORT ACCELERATING MACI UPTAKE AND INCREASED EPICEL USAGE

Dec 07 2017

BRIEF-Vericel reports Q3 loss per share $0.16

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-‍Archon Capital Management reports a 7.56 pct passive stake in Vericel

* Archon Capital Management LLC reports a 7.56 pct passive stake in Vericel Corp of August 23 - SEC filing ​ Source text: (http://bit.ly/2vxJQCK) Further company coverage:

Aug 28 2017

BRIEF-Shanghai Pharmaceuticals Holding to bid for US firm Arbor

* Says it plans to bid for stake in U.S. specialty drug maker Arbor, clarifies media report

Aug 14 2017

BRIEF-Shanghai Fosun Pharmaceutical's unit to bid for US firm Arbor

Aug 14 Shanghai Fosun Pharmaceutical Group Co Ltd

Aug 13 2017

BRIEF-Vericel Q2 loss per share $0.07

* Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 09 2017

Earnings vs. Estimates